You are on page 1of 9

Cell Tissue Res (2011) 343:227235

DOI 10.1007/s00441-010-1034-0


The complement system

J. Vidya Sarma & Peter A. Ward

Received: 2 August 2010 / Accepted: 12 August 2010 / Published online: 14 September 2010
# Springer-Verlag 2010

Abstract The complement system consists of a tightly chemoattraction to apoptosis. Initially, complement was
regulated network of proteins that play an important role in thought to play a major role in innate immunity where a
host defense and inflammation. Complement activation robust and rapid response is mounted against invading
results in opsonization of pathogens and their removal by pathogens. However, recently, it is becoming increasingly
phagocytes, as well as cell lysis. Inappropriate complement evident that complement also plays an important role in
activation and complement deficiencies are the underlying adaptive immunity involving T and B cells that help in
cause of the pathophysiology of many diseases such as elimination of pathogens (Dunkelberger and Song 2010;
systemic lupus erythematosus and asthma. This review Molina et al. 1996) and in maintaining immunologic memory
represents an overview of the complement system in an preventing pathogenic re-invasion. Not only is complement
effort to understand the beneficial as well as harmful roles it involved in innate and adaptive immunity but it is also
plays during inflammatory responses. involved in tissue regeneration, tumor growth (Qu et al. 2009)
and human pathological states such a atypical hemolytic
Keywords Complement . Activation pathways . uremic syndrome, age-related macular degeneration, etc.
Anaphylatoxins (Wagner and Frank 2010).

Introduction Complement activation pathways

Complement was first discovered in the 1890s when it was Complement activation is known to occur through three
found to aid or complement the killing of bacteria by heat- different pathways: alternate, classical and lectin (Fig. 1)
stable antibodies present in normal serum (Walport 2001). The involving proteins that mostly exist as inactive zymogens
complement system consists of more than 30 proteins that are that are then sequentially cleaved and activated. All the
either present as soluble proteins in the blood or are present pathways converge at C3 (which is the most abundant
as membrane-associated proteins. Activation of complement complement protein found in the blood), resulting in the
leads to a sequential cascade of enzymatic reactions (known formation of the activation products, C3a, C3b, C5a and the
as complement activation pathways; see below) resulting in membrane attack complex (C5b-9).
the formation of the potent anaphylatoxins C3a and C5a that
elicit a plethora of physiological responses that range from Alternative pathway

The alternative pathway (AP) is be triggered by carbohy-

This work was supported by NIH grants GM-61656 and HL-31963.
drates, lipids and proteins found on foreign and non-self
J. V. Sarma : P. A. Ward (*) surfaces (Qu et al. 2009). C3 is constantly hydrolyzed at a
Department of Pathology,
The University of Michigan Medical School,
low level (tick over) to form C3b, which binds to targets
1301 Catherine Rd., Box 5602, Ann Arbor, MI 48109-5602, USA such as bacteria. Factor B is then recruited to the bound
e-mail: C3b followed by Factor D that cleaves Factor B to form the
228 Cell Tissue Res (2011) 343:227235

ways of complement activation:
alternative, classical and lectin
pathways; factors that can in-
Pathogen surfaces, LPS IgG and IgM containing Bacterial surfaces
hibit the pathways are indicated + antigen-antibody complexes
in boxes +
Factor B C1q,r,s C1-INH MBL, MASPs

Factor D C4, C2
C3bBb Factor H CR1 C4b, C2a
(C3 convertase) CR1 C4BP (C3 convertase)
C3 C3
stabilizes C3bBbC3b C4bC2aC3b
(C5 convertase) C5 (C5 convertase)

C3b C3a C5a anaphylatoxin
opsonin anaphylatoxin anaphylatoxin
+ C3b
C5b opsonin
Carboxypeptidases C7


C5bC6C7C8(C9)n CD59
Membrane attack

C3 convertase C3bBb, which is stabilized by the presence and C4b. C4b attaches to the surface of the pathogens
of plasma properdin (Kemper et al. 2010). Properdin is a inducing C2 to bind, which is in turn cleaved by MASP2 to
protein released by activated neutrophils (properdin is also form C2b and C2a. C4b together with the attached C2a has
found in macrophages and T cells) and which stabilizes the enzymatic activity and forms the LP C3 convertase
convertase by binding to C3b and preventing its cleavage C4bC2a. The exact role of the other MASPs is presently
by Factors H and I. Recent studies suggest that properdin unknown although MASP1 can cleave C2 but not C4
can directly bind to apoptotic and necrotic cells and initiate (Wallis 2007) and thus help in enhancing complement
complement activation (Kemper et al. 2010). activation by the bound complexes.

Lectin pathway Classical pathway

The lectin pathway (LP) is activated when either mannose The classical pathway (CP) is initiated when immune
binding lectin (MBL) or Ficolin bind to carbohydrate complexes are formed after IgG or IgM binding to pathogens
moieties on surfaces of pathogens including yeast, bacteria, or to other foreign and non-self antigens. The C1 complex, a
parasites and viruses. Both MBL and Ficolin circulate in multimeric complex consisting of C1q, C1r and C1s molecules,
the serum as complexes with MBL-associated proteins then binds to the Fc portion of the IgG or IgM immune
(MASPs; Wallis 2007; Srensen et al. 2005). There are four complex. Activation of C1s and C1r occurs as a consequence of
structurally related MASPs: 1, 2 and 3 and a truncated C1q binding to the exposed Fc portion of IgG or IgM. C1s then
MASP2 known as MAP19 (Srensen et al. 2005). Binding cleaves C4 and C2 to form the CP C3 convertase, C4bC2a.
to pathogens induces conformational changes resulting in In addition, pentraxins (PTX) can recognize pathogens and
autoactivation of MASP2 which cleaves C4 to form C4a eliminate them by directly binding to C1q. Based on their
Cell Tissue Res (2011) 343:227235 229

subunit structure, PTX are divided into two subfamilies: the ways (reviewed in Guo et al. 2004). Originally, C5aR was
short PTX family to which belong the acute phase proteins SAP presumed to be expressed exclusively on myeloid cells but
and CRP and the long PTX family to which belongs the now there is ample evidence that it can be expressed on a
prototype protein PTX3 (Sjberg et al. 2009; Bottazzi et al. variety of non-myeloid cells (Wetsel 1995). Under inflam-
2010). Pentraxins are synthesized in the liver and other tissues matory conditions, expression of C5aR increases in lung
in response to an infection (Bottazzi et al. 2010). endothelial, alveolar and bronchial epithelial cells and
The C3 convertases C4bC2a of CP and LP and C3bBb macrophages (Laudes et al. 2002; Riedemann et al. 2002).
of the AP further cleave C3 to release C3a and C3b. C3b The recently identified C5L2 receptor for C5a is also a
acts as an opsin and helps to further amplify complement seven-transmembrane spanning rhodopsin family receptor.
activation as well as help in phagocytosis. In addition, C3b Abundant expression of C5L2 has been found on neutro-
complexes with the C3 convertases to form the C5 phils and dendritic cells (Ohno et al. 2000). Unlike C3aR
convertases: C3bBbC3b and C4bC2aC3b (Fig. 1). The C5 and C5aR, C5L2 is uncoupled from G-proteins due to an
convertases cleave C5 to form C5a and C5b. The amino-acid replacement of arginine by leucine in the DRY
membrane attack complex (C5b-9, MAC), also called the region at the end of the third intra-cellular transmembrane
terminal complement complex (TCC), is then initiated by loop (Cain and Monk 2002). Following binding of C5a,
C6 and C7 binding to C5b and then C8 and multiple C5L2 does not induce classical signaling (induction of
molecules of C9 binding to the C5bC6C7 complex. The intracellular calcium transients) or cause biological cellular
MAC complex forms a pore by inserting itself into cell responses. The role of C5L2 is largely unknown. It may act
membranes, resulting in cell lysis. as a decoy or scavenger receptor for C5a (Okinaga et al.
2003; Scola et al. 2009). However, recent studies suggest
C3 independent pathways that C5L2 acts as a functional receptor especially in the
setting of sepsis where release of high mobility group box 1
In addition to the above 3 pathways, proteases released by protein requires the presence of C5L2 receptor on macro-
neutrophils and macrophages (Ward and Zvaifler 1973; phages. Blockade of C5L2 along with C5aR greatly
Huber-Lang et al. 2002), factors such as Kallikrein, plasmin improves survival in sepsis when compared to blockade
and factor XIIa (Hageman factor) can generate complement of either receptor alone (Rittirsch et al. 2008a). Under such
activation products. Thrombin, a member of the coagula- conditions, there is a broad suppression in levels of
tion pathway, can locally generate C5a in in vivo in C3- cytokines and chemokines in plasma.
deficient mice which are unable to generate the conven-
tional C5 convertase (Huber-Lang et al. 2006).
Regulation of complement activation

Anaphylatoxins Given the multitude of effects that complement can exert,

there are mechanisms in place to limit complement
The anaphylatoxins C3a and C5a, which consist of 77 and 74 activation where and when it occurs. For example, the
amino acids, respectively (Klos et al. 2009), exert a multitude phlogistic potential of both C3a and C5a is quickly reduced
of effects in inflammatory responses. They act as potent by plasma carboxypeptidases that cleave the C-terminal
chemoattractants for cells such as phagocytes (neutrophils, Arginine, resulting in C3a des-Arg and C5a des-Arg, each
monocytes) to sites of injury or inflammation. They act as of which has less than 10% of their original biological
vasodilators and induce smooth muscle contraction. They activity. C3a des-Arg, which is also known as acylation-
cause histamine release from mast cells and induce oxidative stimulating protein (ASP), is thought to induce triglyceride
bursts (consumption of O2) from neutrophils. They are synthesis in adipocytes (Kalant et al. 2005). C3b and C4b
implicated in the production of the cytokine, TNF, during are also quickly inactivated by proteolytic cleavage into
liver regeneration (Markiewski et al. 2006). C3a and C5a fragments iC3b, C3dg, C3c, C4c, C4d by the serine
exert pleiotropic effects by binding to their respective protease Factor I in the presence of cofactors: membrane
receptors, namely C3aR and, in the case of C5a, to two cofactor protein (MCP) and complement receptor 1 (CR1,
receptors, C5aR and C5a receptor-like 2 receptor (C5L2). CD35) that are membrane bound and Factor H which is
C5L2 was discovered in 2000 (Ohno et al. 2000) and, bound to host surfaces. CR1 promotes phagocytosis,
although it shares homology with C5aR, its exact biologic helping to clear immune complexes by binding to C3b in
function remains unclear. immune complexes. Failure to clear these complexes leads
The classical C5a receptor (C5aR, CD88) belongs to the to deposition of complexes in tissues and activation via Fc
group of seven-transmembrane spanning rhodopsin family receptors, resulting in tissue injury. CR2 (CD21) binds
of receptors that signal through G-protein-dependent path- iC3b, C3dg and C3d (Holers and Kulik 2007). Further-
230 Cell Tissue Res (2011) 343:227235

more, C1 inhibitor (C1-INH) inactivates C1r, C1s and thought that the mutant Factor H protein binds less
MASP2 (Davis et al. 2008). Complement activation is also efficiently to C3b and C3d on endothelial cells and, as a
regulated either by preventing the assembly of the C3 result, there is increased vascular damage, especially to
convertase or, once it is formed, by inhibiting its activity endothelial cells, with resultant intravascular deposition of
due to actions of decay acceleration factor (DAF, CD55), fibrin. However, recently, mutations in Factor I, Factor B
C4 binding protein (C4BP), Factor H and a membrane- and CD 46 have been implicated in aHUS patients (Botto
bound protein found only in rodents, Crry. In addition, the et al. 2009; Pettigrew et al. 2009).
MAC complex formation on cell surfaces or lysis is
negatively regulated by S protein (a plasma glycoprotein Hereditary angioedema
synthesized by endothelial cells), vimentin (a cytoskeletal
protein), and CD59 by interfering with the assembly of the C1 inhibitor (C1-INH) not only inhibits C1r, C1s, and
MAC (Huang et al. 2006). MASP2 of the complement system, but it also inhibits
factor XIIa and kallikrein. Mutations and deficiency of C1-
INH and factor XIIa results in dysregulated bradykinin
Complement regulation of adaptive immunity production, which increases vascular permeability, leading
to angioedema as seen in hereditary angioedema (HAE; for
As early as the 1970s it had become evident that a review, see Cugno et al. 2009). HAE also underscores the
complement not only played a role in pathogen recognition interaction of the proteins involved in the complement,
and elimination but also played a role in B cell biology coagulation and contact proteolytic cascades.
when it was observed that B cells could bind C3 (see
Carroll 2004 for a review). Subsequently, it was recognized Paroxysmal nocturnal hemoglobinuria
that the complement receptors CR1 and CR2 mediate
complement-associated B cell functions. These receptors Complement regulators, CD59 and DAF, are both mem-
are expressed on B cells and follicular dendritic cells as brane bound glycosyl phosphatidylinositol (GPI)-linked
well as on a subset of T cells. Furthermore, the CR2-CD19- molecules that are involved in inhibiting the MAC complex
CD81 complex modulates B-cell receptor signaling, thus and causing dissociation of the C3 and C5 convertases,
affecting the amplitude of B cell responses when presented respectively. The paroxysmal nocturnal hemoglobinuria
with antigens. CR1 and CR2 also appear to play a role in B (PNH) mutation in the gene PIG-A results in decreased
cell differentiation, selection, maintenance and elimination expression of GPI-linked proteins, including CD59 and
of self-reactive B cells (Carroll 2004). DAF. As a result, intense complement-mediated lysis of red
As in the case for B cell biology, it has become blood cells occurs in PNH patients with consequent
increasingly evident that complement also plays an impor- hemolytic anemia. White blood cells are also susceptible
tant role in T cell biology. It affects T cell activation, T cell to lysis, and tissue factor release from these damaged cells
responses and in induction of regulatory T cells (for a may contribute to thrombosis often seen in PNH patients
review, see Kemper and Atkinson 2007). For example, (Liebman and Feinstein 2003).
during T cell activation, absence of DAF on T cells and on
antigen-presenting cells (APC) enhances T cell proliferation Systemic lupus erythematosus
(Heeger et al. 2005). Furthermore, APCs and T cells
express C3aR and C5aR and locally produced C3a and Systemic lupus erythematosus (SLE) syndrome is often
C5a interact with their respective receptors and participate found associated with deficiency in C1q, C1r and C1s
in maintaining T cell viability, proliferation and differenti- (Table 1). SLE in humans is characterized by fever, rash,
ation (Strainic et al. 2008; Lalli et al. 2008). glomerulonephritis and, sometimes, hemolytic anemia. SLE
is associated with the presence of anti-nuclear antibodies
and extractable nuclear antigen (ENA) and absence of anti-
Deficiencies or defects in human complement proteins DNA antibodies. It is thought that absence of key
and biological outcomes complement proteins results in: (1) in defective immune
complex clearance and consequent deposition of the
Hemolytic uremic syndrome complexes in various organs, especially in the kidney and
in arterial walls (causing vasculitis); (2) defective recogni-
Mutation of the factor H gene results in impaired C3 tion of self by B cells leading to autoimmunity; and (3)
convertase activity and is associated with atypical hemo- defective disposal of dying cells including B and T cells,
lytic uremic syndrome (aHUS) wherein hemolytic anemia, again leading to autoimmunity. C2 and C4 deficiency is
thrombocytopenia and acute renal failure develop. It is also associated with development of SLE, although the
Cell Tissue Res (2011) 343:227235 231

Table 1 Complement deficien-

cies and associated clinical Clinical manifestation Complement deficiency
Atypical hemolytic syndrome Factor H
Hereditary angioedema C1-INH
Paroxysmal nocturnal hemoglobinuria CD59 and DAF
Systemic lupus erythematosus C1q, C1r, C1s, C2, C4
Susceptibility to Neisseria meningitides infections C2, C3, C4, C5, C6, C7, C8, C9, properdin
Susceptibility to respiratory tract infections MBL
Susceptibility to recurrent infections MASP2, Factor I

correlation is not as strong as with C1q deficiency. C3 binds the membrane cofactor protein (MCP) and Epstein
deficiency is very rare in humans and does not usually lead virus protein gp350/220 binds to CR2.
to SLE. However, deficiency in C2, C3 and C4 increases Staphylococcus aureus expresses two proteins on its
the susceptibility to infections by bacteria Haemophilus surface: staphylococcal protein A (SPA) and staphylococcal
influenzae and Neisseria (for a comprehensive review on immunoglobulin-binding protein A (Sbi) (Zhang et al.
complement deficiencies and resultant clinical manifesta- 1998) that can bind to the Fc portion of IgG and thus
tions, see Botto et al. 2009; Pettigrew et al. 2009). prevent complement activation and Fc receptor-mediated
phagocytosis. Sbi can also block binding of C1q and thus
Bacterial infections prevent activation. Similarly, group C and G streptococcal
bacteria express protein G that can bind the Fc portion of
There are hardly any known deficiencies of Factor B and IgG. Furthermore, Staphylococcus aureus expresses recep-
Factor D. However, properdin deficiency is known and is tors that bind plasminogen, and Staphylokinase secreted by
associated with mortality from Neisseria meningitides. Staphylococcus aureus cleaves bound plasminogen to
Factor I deficiencies are rare and lead to recurrent bacterial plasmin. Bacterial surface bound plasmin can degrade IgG
infections. MBL deficiency increases susceptibility (Eisen and the opsonin C3b, and thus evade the complement
2010) to respiratory tract infections and MASP2 deficiency system. Further, Staphylococcus aureus-secreted staphylo-
is associated with recurrent infections (Stengaard-Pedersen coccal complement inhibitors (SCINs) inhibit complement
et al. 2003) and has been reported to be found in a number activation. These SCINs bind to C3 convertases and
of different populations including Caucasians, Africans, prevent subsequent steps involved in complement activa-
Brazilians and Chinese (Thiel et al. 2007). Instances of C5, tion, and thus prevent opsonization, phagocytosis and cell
C6, C7, C8 and C9 deficiencies are known and are lysis.
associated with increased susceptibility to Neisseria men- Bacteria also express surface proteins that can bind C4BP
ingitides. However, mortality due to infection is much and Factor H, thereby preventing their cofactor function in
lower than that found with properdin deficiency. Factor I-mediated cleavage of C3b/C4b and the subsequent
downstream complement activation. A number of bacteria
target C4BP for binding and inactivation including the M
Subversion of complement activation by pathogens protein family members Arp and Sir, expressed by group A
Streptococci and outer membrane protein OmpA expressed
Pathogens appear to have evolved strategies to circumvent by Escherichia coli (for a comprehensive review, see Blom
the capabilities of the complement system to eliminate them et al. 2009). Factor H is similarly a target for binding by
by dampening complement activation. Pathogens accom- proteins expressed by a number of bacteria including M
plish this evasion by affecting every facet of complement protein expressed by Staphylococcus aureus and Streptococ-
activation, including regulation of activation, amplification, cus pyogenes and GNA1870 expressed by Neisseria
opsonization, phagocytosis, chemoattraction, cell lysis (for meningitides (Blom et al. 2009).
a review, see Lambris et al. 2008; Rooijakkers and van Similarly, complement-inhibiting proteins expressed by
Strijp 2007) by either proteolysis of complement proteins or viruses such as vaccinia, cowpox and smallpox block C3
mimicking the action of complement proteins or interacting convertase formation (for a review see (Tortorella et al.
with complement proteins. As will be seen below Staphy- 2000). These inhibitory proteins contain short consensus
lococcus aureus is a good example of a pathogen that repeats (SCR) that are also found in complement proteins
subverts all these processes. Pathogens also take advantage (such as Factor B) (Ricklin and Lambris 2007). In addition,
of complement by binding to membrane bound complement parasites such as Schistosoma and Trypanosoma express on
proteins to gain entry into cells. For example, measles virus their surface complement C2 receptor inhibitor trispanning
232 Cell Tissue Res (2011) 343:227235

(CRIT) protein that inhibits C3 convertase by binding to C2 role in the pathophysiology of asthma and the acute
(Cestari Idos et al. 2009; Inal and Sim 2000). respiratory distress syndrome (reviewed in Wills-Karp
Pathogens can also prevent recruitment of phagocytic cells 2007; Sarma et al. 2006). Asthma is a chronic inflammatory
by inhibiting C5a and C5aR interaction. For example, the upper airway disease with increasing prevalence throughout
Staphylococcus aureus product, chemotaxis-inhibiting pro- the world and especially in young children in the developed
tein of Staphylococcus aureus (CHIPS), can bind to C5aR world. In asthma, hyper-secretion of mucus occurs in the
and prevent C5a-mediated signaling, although CHIPS and airways along with smooth muscle proliferation in upper
C5a share hardly any homology but are similar in overall airway (bronchial/bronchiolar) walls together with in-
structure and size. Another Staphylococcus aureus product, creased numbers of mast cells, CD4+ T cells and
SSL-7, can bind C5 and inhibit its cleavage preventing MAC eosinophils. This leads to obstructed airways and accentu-
formation (Rooijakkers and van Strijp 2007). ated upper airway contractile responses leading to shortness
of breath, wheezing and coughing. In ARDS, there is a
severe impairment of gas exchange due to damage to the
Consequences of dysregulated complement activation alveolar and vascular epithelium resulting in increased
permeability of plasma contents and influx of neutrophils
As described above the complement system plays a critical into the interstitial and alveolar spaces.
role in both innate and adaptive immune responses. Clearly Clinical studies show that elevated levels of C3a and
pathogens go to great lengths to avoid complement C5a occur in bronchoalveolar lavage (BAL) fluids of
activation. Deficiencies in complement proteins can lead individuals with asthma and ARDS when compared to
to serious consequences resulting in diseases such as lupus, healthy individuals (Wills-Karp 2007). Elevated levels of
HUS, etc. On the other hand, excessive complement C3a and C5a may also be found in the serum of ARDS
activation or dysregulated modulation may contribute to patients. Similarly, in septic patients, elevated levels of the
several diseases and pathological conditions such as MAC complex precede the development of ARDS (Lan-
multiple sclerosis (Ingram et al. 2009), Alzheimers (Kolev glois and Gawryl 1988). There is substantial evidence
et al. 2009), asthma (Wills-Karp 2007), COPD (Sarma et al. suggesting that varied environmental factors trigger com-
2006), sepsis (Ward 2008), hyperacute organ rejection plement activation at the airway interface, leading to
(Wasowska 2010), etc. In sepsis, excessive C5a generation recruitment of cells that release inflammatory mediators
is thought to contribute to increased thymocyte apoptosis resulting in further exacerbation of the inflammatory
and consumptive coagulopathy, decreased innate immune process in asthma and ARDS (Wills-Karp 2007). For
functions of neutrophils, cardiomyopathy and multiple example, TNF and IL-1 generated from inflammatory
organ failure (for review, see Rittirsch et al. 2008b). cells induce up-regulation of adhesion molecules (ICAM-1
Complement proteins C3 and C1q are thought to bind to and E-selectin) on vascular endothelial cells and in
amyloid-beta proteins in the brain in the early stages of the pulmonary epithelial cells, which results in tethering of
Alzheimers syndrome, and subsequent complement- neutrophils to these surfaces. Neutrophils can exert further
mediated lysis of neurons may further exacerbate the tissue damage by releasing myeloperoxidase, elastase, etc.
syndrome. In ischemia/reperfusion injury of tissues, com- Examples of environmental triggers that activate comple-
plement activation during the reperfusion phase is thought ment are seen in elevated BAL C3 levels in humans
to contribute to the ensuing inflammation. Age-related exposed to ozone, and elevated serum C3 levels in children
macular degeneration is thought to occur due to excessive with chronic exposure to cigarette smoke. It has been
complement activation (Zipfel et al. 2007) and appears to suggested that proteases released from infiltrating cells into
be related to defective Factor H attachment to the Bruchs the airways can directly cleave C3 and C5, thereby
membrane in the retina, leading to protein deposits on the generating C3a and C5a. Alternatively, antibody-
membrane known as Drusen. Excessive complement containing immune complexes as well as carbohydrate
activation has also been associated with disease severity moieties and macromolecular structures present on patho-
in patients infected with malaria (reviewed in Silver et al. gens and allergens can activate all three complement
2010). Interestingly, C5 deficiency or intercepting C5a and pathways. It is likely that complement gets activated by a
C5aR interaction has a protective effect in an animal model number of different pathways in asthma and ARDS,
of cerebral malaria (Patel et al. 2008). although the exact mechanisms are not fully understood.
Asthma and the acute response distress syndrome Thus, given above are a few examples of the pathology
(ARDS) are two of the more well-known examples of of dysregulated complement activation. For more examples
dysregulated complement activation. It is now well estab- of the role of complement in allergic asthma, transplant
lished from both experimental models of sepsis and clinical rejection, cancer and autoimmune diseases, see Huber-Lang
studies in humans that the complement system plays a key et al. (2002).
Cell Tissue Res (2011) 343:227235 233

Complement-based therapeutics to C5a and C5b. The antibody does not seem to activate
complement or bind to the host Fc receptor.
Given the growing recognition of complement in several
pathological conditions, there has been a concerted effort
recently in designing therapeutics aimed at complement Conclusion
proteins (Ricklin and Lambris 2007). Understanding subver-
sion tactics of pathogens can help in designing therapeutic The complement system is composed of a network of proteins
interventions when unwanted or runaway complement activa- that play an important role in innate and adaptive immunity that
tion does more harm than good. It has been a challenge to range from opsonization of pathogens and chemoattraction to
design effective therapeutic interventions, although a number removal of apoptotic and necrotic cells. Activation of the
of soluble and membrane-bound complement proteins are system is exquisitely regulated, and inappropriate activation
available as potential therapeutic targets. One of the main either due to deficiencies in key complement proteins or due to
problems is the lack of understanding of the exact molecular dysregulated activation has adverse consequences. There is also
mechanisms involved in complement-mediated disease pa- a growing appreciation that there is cross-talk between the
thology (reviewed in Ricklin and Lambris 2007). For instance, complement system and other systems, especially the coagu-
a good example is the use of compstatin, a synthetic lation system (Kourtzelis et al. 2010). For example, C5a-
compound that blocks the C3 convertase. An ideal use of mediated tissue factor release from neutrophils has been
compstatin would be for treatment of patients experiencing implicated in the pathogenesis of thrombosis in patients on
age-related macular degeneration, using intravitreal injection hemodialysis.
into the eye, much as is now done with blocking mAb to
VEGF. On the other hand, systemic treatment of septic
patients with compstatin runs the risk of excessive blocking of References
the C3 convertase, which would compromise the production
of the vital opsonic factors, C3b and iC3b. Accordingly, this Blom AM, Hallstrm T, Riesbeck K (2009) Complement evasion
presents the dilemma for using complement inhibitors that strategies of pathogens-acquisition of inhibitors and beyond. Mol
target the C3 convertase. The lack of sufficient knowledge Immunol 46(14):28082817
Bottazzi B, Doni A, Garlanda C, Mantovani A (2010) An integrated
about details of complement activation (including the com- view of humoral innate immunity: pentraxins as a paradigm.
plement regulatory proteins) makes it difficult to predict the Annu Rev Immunol 28:157183
efficacy of complement inhibitors that would be given Botto M, Kirschfink M, Macor P, Pickering MC, Wrzner R, Tedesco
systemically. F (2009) Complement in human diseases: Lessons from
complement deficiencies. Mol Immunol 14:27742783
Another example of a dilemma related to in vivo blockade of Cain SA, Monk PN (2002) The orphan receptor C5L2 has high
complement comes from recent studies involving mice with affinity binding sites for complement fragments C5a and C5a
CLP-induced sepsis (Flierl et al. 2008). Use of a blocking des-Arg(74). J Biol Chem 277:71657169
antibody to C5a was highly protective. However, when C6 Carroll MC (2004) The complement system in B cell regulation. Mol
Immunol 41(2-3):141146
was depleted in order to prevent formation of the MAC (C5b- Cestari Idos S, Krarup A, Sim RB, Inal JM, Ramirez MI (2009) Role
9), it was found that the bacterial burden in blood was much of early lectin pathway activation in the complement-mediated
higher in CLP mice compared to complement-intact mice, killing of Trypanosoma cruzi. Mol Immunol 47(23):426437
consistent with the knowledge that C5b-9 has lytic activity for Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M (2009) C1-
inhibitor deficiency and angioedema: molecular mechanisms and
bacteria. Accordingly, since complement is both a potent clinical progress. Trends Mol Med 15(2):6978
inflammatory-inducing system as well as critically important Davis AE 3rd, Mejia P, Lu F (2008) Biological activities of C1
for innate immune defenses, we need to have a much better inhibitor. Mol Immunol 45(16):40574063
understanding of how the system really works. Dunkelberger JR, Song WC (2010) Complement and its role in innate
and adaptive immune responses. Cell Res 20(1):3450
Further, therapeutic strategies need to take into account the Eisen DP (2010) Mannose-binding lectin deficiency and respiratory
delicate balance between suppression of complement-mediated tract infection. J Innate Immun 2(2):114122
disease pathology and compromise of complement-mediated Flierl MA, Rittirsch D, Nadeau BA, Day DE, Zetoune FS, Sarma JV,
defense and immunity. After several attempts, several small Huber-Lang MS, Ward PA (2008) Functions of the complement
components C3 and C5 during sepsis. FASEB J 22(10):34833490
molecules inhibitors such as compstatin that prevents C3 Guo RF, Riedemann NC, Ward PA (2004) Role of C5a-C5aR
cleavage, PMX-53 that is a C5aR antagonist are in either interaction in sepsis. Shock 21(1):17
preclinical or clinical phases of testing (Qu et al. 2009). Only Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y,
eculizumab (trade name Soliris), which is a humanized Medof ME (2005) Decay-accelerating factor modulates induction
of T cell immunity. J Exp Med 201(10):15231530
monoclonal antibody directed against C5, has been approved Holers VM, Kulik L (2007) Complement receptor 2, natural anti-
by the United States Food and Drug Administration for use in bodies and innate immunity: Inter-relationships in B cell
patients with PNH. This antibody prevents the cleavage of C5 selection and activation. Mol Immunol 44(1-3):6472
234 Cell Tissue Res (2011) 343:227235

Huang Y, Qiao F, Abagyan R, Hazard S, Tomlinson S (2006) Defining Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade
the CD59-C9 binding interaction. J Biol Chem 281(37):27398 MB, Brodbeck RM, Krause JE, Choe HR, Gerard NP et al (2003)
27404. doi:10.1074/jbc.M603690200 C5L2, a nonsignaling C5A binding protein. Biochemistry
Huber-Lang M, Younkin EM, Sarma JV, Riedemann N, McGuire SR, Lu 42:94069415
KT, Kunkel R, Younger JG, Zetoune FS, Ward PA (2002) Generation Patel SN, Berghout J, Lovegrove FE, Ayi K, Conroy A, Serghides L,
of C5a by phagocytic cells. Am J Pathol 161(5):18491859 Min-oo G, Gowda DC, Sarma JV, Rittirsch D, Ward PA, Liles WC,
Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire Gros P, Kain KC (2008) C5 deficiency and C5a or C5aR blockade
SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, protects against cerebral malaria. J Exp Med 205(5):11331143
Younger JG, Drouin SM, Wetsel RA, Ward PA (2006) Genera- Pettigrew HD, Teuber SS, Gershwin ME (2009) Clinical significance
tion of C5a in the absence of C3: a new complement activation of complement deficiencies. Ann N Y Acad Sci 1173:108123
pathway. Nat Med 12(6):682687 Qu H, Ricklin D, Lambris JD (2009) Recent developments in low
Inal JM, Sim RB (2000) A Schistosoma protein, Sh-TOR, is a novel molecular weight complement inhibitors. Mol Immunol 47(2
inhibitor of complement which binds human C2. FEBS Lett 470 3):185195
(2):131134 Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat
Ingram G, Hakobyan S, Robertson NP, Morgan BP (2009) Comple- Biotechnol 25(11):12651275
ment in multiple sclerosis: its role in disease and potential as a Riedemann NC, Guo RF, Sarma VJ, Laudes IJ, Huber-Lang M,
biomarker. Clin Exp Immunol 155(2):128139 Warner RL, Albrecht EA, Speyer CL, Ward PA (2002)
Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA, Expression and function of the C5a receptor in rat alveolar
Cianflone K (2005) C5L2 is a functional receptor for acylation- epithelial cells. J Immunol 168:19191925
stimulating protein. J Biol Chem 280(25):2393623944 Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay
Kemper C, Atkinson JP (2007) T-cell regulation: with complements CR, Zetoune FS, Gerard NP, Cianflone K, Khl J, Gerard C,
from innate immunity. Nat Rev Immunol 7(1):918 Sarma JV, Ward PA (2008a) Functional roles for C5a receptors in
Kemper C, Atkinson JP, Hourcade DE (2010) Properdin: emerging sepsis. Nat Med 14(5):551557
roles of a pattern-recognition molecule. Annu Rev Immunol Rittirsch D, Flierl MA, Ward PA (2008b) Harmful molecular
28:131155 mechanisms in sepsis. Nat Rev Immunol 8(10):776787
Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Khl J (2009) Rooijakkers SH, van Strijp JA (2007) Bacterial complement evasion.
The role of the anaphylatoxins in health and disease. Mol Mol Immunol 44(13):2332
Immunol 46(14):27532766 Sarma VJ, Huber-Lang M, Ward PA (2006) Complement in lung
Kolev MV, Ruseva MM, Harris CL, Morgan BP, Donev RM (2009) disease. Autoimmunity 39(5):387394
Implication of complement system and its regulators in Alz- Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN (2009) The
heimer's disease. Curr Neuropharmacol 7(1):18 human complement fragment receptor, C5L2, is a recycling
Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, decoy receptor. Mol Immunol 46(6):11491162
Mitroulis I, Panagoutsos S, Passadakis P, Vargemezis V, Magotti Silver KL, Higgins SJ, McDonald CR, Kain KC (2010) Complement
P, Qu H, Mollnes TE, Ritis K, Lambris JD (2010) Complement driven innate immune response to malaria: fuelling severe malarial
anaphylatoxin C5a contributes to hemodialysis-associated throm- diseases. Cell Microbiol 12(8):10361045, Epub 2010 Jun 11
bosis. Blood 116(4):631639 Sjberg AP, Trouw LA, Blom AM (2009) Complement activation and
Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS (2008) inhibition: a delicate balance. Trends Immunol 30(2):8390
Locally produced C5a binds to T cell-expressed C5aR to enhance Srensen R, Thiel S, Jensenius JC (2005) Mannan-binding-lectin-
effector T-cell expansion by limiting antigen-induced apoptosis. associated serine proteases, characteristics and disease associa-
Blood 112:17591766 tions. Semin Immunopathol 27(3):299319
Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion Stengaard-Pedersen K, Thiel S, Gadjeva M, Mller-Kristensen M,
by human pathogens. Nat Rev Microbiol 6(2):132142 Srensen R, Jensen LT, Sjholm AG, Fugger L, Jensenius JC
Langlois PF, Gawryl MS (1988) Accentuated formation of the (2003) Inherited deficiency of mannan-binding lectin-associated
terminal C5b-9 complement complex in patient plasma precedes serine protease 2. N Engl J Med 349(6):554560
development of the adult respiratory distress syndrome. Am Rev Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS,
Respir Dis 138:368375 Dubyak GR, Heeger PS, Medof ME (2008) Locally produced
Laudes IJ, Chu JC, Huber-Lang M, Guo RF, Riedemann NC, Sarma complement fragments C5a and C3a provide both costimulatory
JV, Mahdi F, Murphy HS, Speyer C, Lu KT et al (2002) and survival signals to naive CD4+ T cells. Immunity 28(3):425
Expression and function of C5a receptor in mouse microvascular 435
endothelial cells. J Immunol 169:59625970 Thiel S, Steffensen R, Christensen IJ, Ip WK, Lau YL, Reason IJ,
Liebman HA, Feinstein DI (2003) Thrombosis in patients with Eiberg H, Gadjeva M, Ruseva M, Jensenius JC (2007)
paroxysmal nocturnal hemoglobinuria is associated with mark- Deficiency of mannan-binding lectin associated serine protease-
edly elevated plasma levels of leukocyte-derived tissue factor. 2 due to missense polymorphisms. Genes Immun 8(2):154163
Thromb Res 111(45):235238 Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL (2000)
Markiewski MM, DeAngelis RA, Lambris JD (2006) Liver inflammation Viral subversion of the immune system. Annu Rev Immunol
and regeneration: two distinct biological phenomena or parallel 18:861926
pathophysiologic processes? Mol Immunol 43(12):4556 Wagner E, Frank MM (2010) Therapeutic potential of complement
Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, modulation. Nat Rev Drug Discov 9(1):4356
Strauss-Schoenberger J, Karr RW, Chaplin DD (1996) Markedly Wallis R (2007) Interactions between mannose-binding lectin and
impaired humoral immune response in mice deficient in comple- MASPs during complement activation by the lectin pathway.
ment receptors 1 and 2. Proc Natl Acad Sci USA 93(8):33573361 Immunobiology 212(45):289299
Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA Walport MJ (2001) Complement. First of two parts. N Engl J Med 344
(2000) A putative chemoattractantreceptor, C5L2, is expressed in (14):10581066, Review
granulocyte and immature dendritic cells, but not in mature Ward PA (2008) Sepsis, apoptosis and complement. Biochem
dendritic cells. Mol Immunol 37:407412 Pharmacol 76(11):13831388
Cell Tissue Res (2011) 343:227235 235

Ward PA, Zvaifler NJ (1973) Quantitative phagocytosis by neutrophils. Wills-Karp M (2007) Complement activation pathways: a bridge
II. Release of the C5-cleaving enzyme and inhibition of phagocy- between innate and adaptive immune responses in asthma. Proc
tosis by rheumatoid factor. J Immunol 111(6):17771782 Am Thorac Soc 4(3):247251
Wasowska BA (2010) Mechanisms involved in antibody- and Zhang L, Jacobsson K, Vasi J, Lindberg M, Frykberg L (1998) A
complement-mediated allograft rejection. Immunol Res 47(1 second IgG-binding protein in Staphylococcus aureus. Microbi-
3):2544 ology 144(Pt 4):985991
Wetsel RA (1995) Expression of the complement C5a anaphylatoxin Zipfel PF, Wrzner R, Skerka C (2007) Complement evasion of
receptor (C5aR) on non-myeloid cells. Immunol Lett 44:183 pathogens: common strategies are shared by diverse organisms.
187 Mol Immunol 44(16):38503857